Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER3 | P43115 | 16/20 | 1.00 |
| ▸ | PTGER4 | P35408 | 8/20 | 1.00 |
| ▸ | PTGER1 | P34995 | 5/20 | 1.00 |
| ▸ | DRD3 | P35462 | 1/20 | 1.00 |
| ▸ | PTGER2 | P43116 | 5/20 | 0.60 |
| ▸ | PTGDR | Q13258 | 2/20 | 0.51 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.51 |
| ▸ | PTGFR | P43088 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | GLA | P06280 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6651946 | 1.00 | PTGER3 (1.00) | PTGER3PTGER4PTGER1DRD3PTGER2 | |
| SCHEMBL29988642 | 1.00 | PTGER3 (1.00) | PTGER3PTGER4PTGER1DRD3PTGER2 | |
| SCHEMBL29663670 | 1.00 | PTGER3 (1.00) | PTGER3PTGER4PTGER1DRD3PTGER2 | |
| SCHEMBL29376849 | 1.00 | PTGER3 (1.00) | PTGER3PTGER4PTGER1DRD3PTGER2 | |
| SCHEMBL7929853 | 0.92 | PTGER3 (0.86) | PTGER3PTGER4PTGER1DRD3PTGER2 | |
| SCHEMBL7929856 | 0.92 | PTGER3 (0.86) | PTGER3PTGER4PTGER1DRD3PTGER2 | |
| SCHEMBL7928529 | 0.92 | PTGER3 (0.84) | PTGER3PTGER4PTGER1DRD3PTGER2 | |
| SCHEMBL7928538 | 0.92 | PTGER3 (0.84) | PTGER3PTGER4PTGER1DRD3PTGER2 | |
| SCHEMBL7928536 | 0.92 | PTGER3 (0.84) | PTGER3PTGER4PTGER1DRD3PTGER2 | |
| SCHEMBL7817274 | 0.91 | PTGER3 (0.83) | PTGER3PTGER4PTGER1DRD3PTGER2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2019071353-A1 | USE OF SYSTEM XC- INHIBITOR FOR TREATING STATIN-INDUCED MYALGIA | EXERKINE CORPORATION (CA) | 2019-04-18 | — | — | WO | claimed |
| US-20240261296-A1 | THERAPEUTIC MODALITIES FOR INHIBITING PANCREATIC BETA CELL IMPAIRMENT AND TREATING DIABETES | Hadasit Medical Research Serices & Development Ltd. (IL) | 2024-08-08 | — | — | US | disclosed |
| EP-4319734-A2 | PROSTAGLANDIN RECEPTOR 3 (EP3) ANTAGONISTS FOR USE IN THE TREATMENT OF DIABETES | Hadasit Medical Research Services&Development Ltd. (IL) | 2024-02-14 | — | — | EP | disclosed |
| US-20220088040-A1 | Use of System XC-Inhibitor for Treating Statin-Induced Myalgia | EXERKINE CORP (CA) | 2022-03-24 | — | — | US | disclosed |
| US-10105351-B2 | Neurofibromatoses therapeutic agents and screening for same | UNIVERSITY OF CENTRAL FLORIDA RESEARCH FOUNDATION, INC. (US) | 2018-10-23 | — | — | US | disclosed |
| EP-2825209-B1 | NEUROFIBROMATOSES THERAPEUTIC AGENTS AND SCREENING FOR SAME | UNIV CENTRAL FLORIDA RES FOUND INC (US) | 2018-08-29 | — | — | EP | disclosed |
| US-20160303059-A1 | E-PROSTANOID RECEPTOR, PTGER3, AS A NOVEL ANTI-DIABETIC THERAPEUTIC TARGET | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-10-20 | — | — | US | disclosed |
| US-9381176-B2 | E-prostanoid receptor, Ptger3, as a novel anti-diabetic therapeutic target | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2016-07-05 | — | — | US | disclosed |
| US-20150065554-A1 | NEUROFIBROMATOSES THERAPEUTIC AGENTS AND SCREENING FOR SAME | UNIVERSITY OF CENTRAL FLORIDA RESEARCH FOUNDATION, INC. (US) | 2015-03-05 | — | — | US | disclosed |
| EP-2825209-A1 | NEUROFIBROMATOSES THERAPEUTIC AGENTS AND SCREENING FOR SAME | University of Central Florida Research Foundation, Inc. (US) | 2015-01-21 | — | — | EP | disclosed |
| WO-2013138463-A1 | NEUROFIBROMATOSES THERAPEUTIC AGENTS AND SCREENING FOR SAME | UNIVERSITY OF CENTRAL FLORIDA RESEARCH FOUNDATION, INC. (US) | 2013-09-19 | — | — | WO | disclosed |
| US-20130244932-A1 | E-PROSTANOID RECEPTOR, PTGER3, AS A NOVEL ANTI-DIABETIC THERAPEUTIC TARGET | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2013-09-19 | — | — | US | disclosed |
| US-20080200568-A1 | Genes Associated With Type ll Diabetes Mellitus | SMITHKLINE BEECHAM CORPORATION | 2008-08-21 | — | — | US | disclosed |
| US-20080200568-A1 | Genes Associated With Type ll Diabetes Mellitus | SMITHKLINE BEECHAM CORPORATION | 2008-08-21 | — | — | US | disclosed |
| WO-2007027630-A2 | GENES ASSOCIATED WITH TYPE II DIABETES MELLITUS | SMITHKLINE BEECHAM CORPORATION (US) | 2007-03-08 | — | — | WO | disclosed |
| US-20040235955-A1 | Remedies for pruritus | ONO PHARMACEUTICAL CO., LTD. (JP) | 2004-11-25 | — | — | US | disclosed |
| EP-1426059-A1 | REMEDIES FOR PRURITUS | ONO PHARMACEUTICAL CO., LTD. (JP) | 2004-06-09 | — | — | EP | disclosed |
| US-6242493-B1 | PROSTAGLANDIN INHIBITORS; ANALGESICS, ANTIPYRETICS, ANTIINFLAMMATORY AGENTS | MERCK FROSST CANADA & CO. (CA) | 2001-06-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150065554-A1 | NEUROFIBROMATOSES THERAPEUTIC AGENTS AND SCREENING FOR SAME | VHL, DIAPH1, TSG101 | PTGER3 3378/4885PTGER4 3629/4885PTGER1 3399/4885 |
| US-20240261296-A1 | THERAPEUTIC MODALITIES FOR INHIBITING PANCREATIC BETA CELL IMPAIRMENT AND TREATING DIABETES | IAPP, PTGER3, GPR119 | PTGER3 2/4885PTGER4 10/4885PTGER1 6/4885 |
| US-20080200568-A1 | Genes Associated With Type ll Diabetes Mellitus | PTGES3, ELOVL3, PTGER3 | PTGER3 3/4885PTGER4 27/4885PTGER1 22/4885 |
| US-10105351-B2 | Neurofibromatoses therapeutic agents and screening for same | VHL, DIAPH1, TSG101 | PTGER3 3378/4885PTGER4 3629/4885PTGER1 3399/4885 |
| US-20040235955-A1 | Remedies for pruritus | PTGER3, PTGER2, PTGER1 | PTGER3 1/4885PTGER4 8/4885PTGER1 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.